TIMM21: A Promising Drug Target and Biomarker for Chronic Pain

Target Name: TIMM21

NCBI ID: G29090

TIMM21

TIMM21: A Promising Drug Target and Biomarker for Chronic Pain

Abstract:

Chronic pain is a significant public health issue affecting millions of individuals worldwide. The TIMM21 gene, located on chromosome 18, has been identified as a potential drug target and biomarker for chronic pain. This article summarizes the current research on TIMM21 and its potential as a drug target and biomarker for chronic pain.

Introduction:

Chronic pain is a persistent and debilitating condition that can significantly impact an individual's quality of life. According to the World Health Organization (WHO), chronic pain affects approximately 12% of the global population, with costs estimated at $63 billion annually. Chronic pain can be caused by various conditions, including musculoskeletal, neuropathic, and inflammatory diseases.

Recent studies have identified several potential drug targets and biomarkers for chronic pain, including the TIMM21 gene. TIMM21 is a non-coding RNA gene located on chromosome 18, and its expression has been associated with various pain modalities, including nociception, pain perception, and neuroinflammation.

Potential as a Drug Target:

The TIMM21 gene has been identified as a potential drug target for chronic pain due to its involvement in the modulation of pain signaling pathways. Research has found that TIMM21 has been shown to regulate the activity of several pain-related genes, including TrkA, TrkB, and TrkC, which encode for proteins involved in nociception, neuroinflammation, and pain perception.

In addition, TIMM21 has been shown to play a role in the regulation of pain modalities, including pain processing and neuroinflammation. For instance, studies have shown that TIMM21-deficient mice exhibit increased pain sensitivity and hyperalgesia, while TIMM21-proficient mice exhibit reduced pain sensitivity and hyperalgesia.

The potential drug targets for TIMM21 include small molecule inhibitors, RNA-based therapeutics, and diagnostic probes. Small molecule inhibitors have been shown to be effective in reducing pain sensitivity in animal models of chronic pain. RNA-based therapeutics, such as RNA interference ( RNAi) probes, have also shown promise in targeting TIMM21 in animal models of chronic pain.

Potential as a Biomarker:

TIMM21 has also been identified as a potential biomarker for chronic pain due to differences in its expression levels between healthy and painful subjects. Studies have shown that the expression of TIMM21 is significantly increased in the pain-associated tissues, including the liver, spleen, and kidneys, of animal models of chronic pain.

In addition, TIMM21 has been shown to be involved in the regulation of pain signaling pathways, which could make it an attractive biomarker for assessing the efficacy of pain treatments. For instance, studies have shown that administration of a small molecule inhibitor of TIMM21 reduced pain in animal models of chronic pain, while an RNA-based therapeutic targeting TIMM21 also reduced pain in animal models of chronic pain.

Conclusion:

In conclusion, the TIMM21 gene has been identified as a potential drug target and biomarker for chronic pain. Its involvement in the modulation of pain signaling pathways and its expression levels in pain-associated tissues make it an attractive target for small molecule inhibitors, RNA- based therapeutics, and diagnostic probes. Further research is needed to fully understand the role of TIMM21 in chronic pain and to develop effective treatments.

Protein Name: Translocase Of Inner Mitochondrial Membrane 21

Functions: Participates in the translocation of transit peptide-containing proteins across the mitochondrial inner membrane. Also required for assembly of mitochondrial respiratory chain complex I and complex IV as component of the MITRAC (mitochondrial translation regulation assembly intermediate of cytochrome c oxidase complex) complex. Probably shuttles between the presequence translocase and respiratory-chain assembly intermediates in a process that promotes incorporation of early nuclear-encoded subunits into these complexes

The "TIMM21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TIMM21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets